Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - flucloxacillin sodium - powder for solution for injection/infusion - 1000 milligram(s) - flucloxacillin

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - flucloxacillin sodium - powder for solution for injection/infusion - 2000 milligram(s) - flucloxacillin

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - flucloxacillin sodium - powder for solution for injection/infusion - 500 milligram(s) - flucloxacillin

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - flucloxacillin sodium - oral capsule - 250mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - flucloxacillin sodium - oral capsule - 500mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

asclemed usa, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 271.2 mg (equivalent: dicloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; purified water; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 542.52 mg (equivalent: dicloxacillin sodium, qty 500 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide; patent blue v; quinoline yellow - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 271.26 mg (equivalent: dicloxacillin, qty 250 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.